The Psychedelics Newsletter

NeonMind’s President and CEO, Robert Tessarolo, on psilocybin’s efficacy in treating obesity; MDMA, LSD and magic mushrooms: are these drugs the future of therapy? CaaMTech raises US$22m in Series A funding round

Tryp Therapeutics’ CEO Greg McKee on the next wave of psychedelic medicines; The worldview-changing drugs poised to go mainstream; The DEA bolsters bolsters support for psychedelic research

RYAH Group's CEO Gregory Wagner on drug delivery through IoT Awakn Life Sciences to conduct ketamine trials for gambling addiction California bill to legalise psychedelics shelved until 2022

Psychedelic-assisted therapy enhanced through VR technology; California bill to legalise psychedelics clears another hurdle; Biomind Labs' Phase II clinical trial approved by Brazilian regulator

Beckley Psytech’s CEO Cosmo Feilding Mellen on raising US$80 million; Awakn Life Sciences begins trading on OTCQB; atai Life Sciences creates subsidiary for salvia divinorum derivatives. Read more in Issue 42 of the Psychedelics Newsletter.

Overwhelming majority of Canadians support legalisation of psilocybin; Could psychedelic drugs revolutionise mental healthcare in the UK? Cybin becomes first psychedelic company to list on the New York Stock Exchange. Read more in Issue 41 of the Psychedelics Newsletter

BHMNC Brain Health on precision psychiatry and psychedelics; Global psychedelics research institute launched in Melbourne with AU$40m in funding; Poll reveals majority of Canadians support legalisation of psilocybin-assisted therapy. Read more in Issue 40 of the Psychedelics Newsletter

Field Trip’s Co-founder and Executive Chairman Ronan Levy on investor opportunities following Nasdaq listing; Cybin to list on NYSE’s Small Cap Market to finance expansion; The Times: Psychedelic firms take a trip over the Atlantic in search of funds. Read more in Issue 39 of the Psychedelics Newsletter.

Biden calls for lower drug prices: should psychedelics investors be concerned? Jamaica adopts protocols for cultivating and possessing psilocybin; Nasdaq explores the growth of the psychedelic industry. Read more in Issue 38 of the Psychedelics Newsletter

Data science driving innovation in psychedelic medicine; Looking back on the PSYCH Investor Summit: Research & Development; atai Life Sciences’ Founder warns decriminalisation could set back regulation. Read more in Issue 37 of the Psychedelics Newsletter.

PSYCH Investor Summit: Research & Development kicks off today; Tryp Therapeutics to treat psychiatric disorders; Braxia Scientific identifies short-term ROI in psychedelic medicine. Read more in Issue 36 of the Psychedelics Newsletter.

One week remains until the PSYCH Investor Summit: Research & Development; Texas legalises medical psychedelic research; Compass Pathways conducts world’s largest psilocybin trial to-date. Read more in Issue 35 of The Psychedelics Newsletter.